Document is current
Any future updates will be listed below
-
Authors
Sawant, Mithila
Wilson, Audrey
Sridaran, Dhivya http://orcid.org/0000-0003-4401-8571
Mahajan, Kiran http://orcid.org/0000-0001-7192-396X
O’Conor, Christopher J.
Hagemann, Ian S. http://orcid.org/0000-0002-3855-9745
Luo, Jingqin http://orcid.org/0000-0003-2759-3072
Weimholt, Cody
Li, Tiandao http://orcid.org/0000-0003-1650-0555
Roa, Juan Carlos
Pandey, Akhilesh http://orcid.org/0000-0001-9943-6127
Wu, Xinyan
Mahajan, Nupam P. http://orcid.org/0000-0002-4150-602X
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0202)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA20825)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (5R01CA227025)
- License Information
-
More Information
Article History
Received: 31 August 2022
Revised: 16 May 2023
Accepted: 8 June 2023
First Online: 17 June 2023
Competing interests
: A patent “Inhibitors of ACK1/TNK2 Tyrosine Kinase” (patent no. 9,850,216; 10,017,478 and 10,336,734) covers (<i>R</i>)-<b>9b</b> compound. NPM and KM are named as inventors. These patents have been licensed by TechnoGenesys Inc. KM and NPM are co-founders of TechnoGenesys Inc., own stocks, and serve as consultants for TechnoGenesys Inc. The other authors declare no potential conflicts of interest.
